The difficult-to-express proteins market size has grown rapidly in recent years. It will grow from $4.11 billion in 2023 to $4.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.6%. The growth observed in the historical period can be attributed to increased market demand for protein therapeutics, challenges encountered in drug development, advancements in the biopharmaceutical sector, limitations in existing technologies, and the evolution of gene editing and engineering practices.
The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $7.09 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%.The anticipated growth in the forecast period is expected to result from the development of novel expression systems, advancements in next-generation gene editing tools, improvements in cell-free systems, enhanced protein engineering, and the integration of artificial intelligence and machine learning. Key trends expected in the forecast period include the adoption of innovative protein folding technologies, increased utilization of synthetic biology, targeted protein modification, advancements in biophysical characterization, and the expanded use of CRISPR/Cas technology.
The anticipated surge in demand for recombinant proteins is poised to drive the expansion of the difficult-to-express protein market in the foreseeable future. Recombinant proteins, synthesized using modified DNA, play a crucial role in generating the genetic codes necessary for desired proteins. These difficult-to-express proteins, integral in recombinant protein synthesis, enable the exploration of specific activities, protein-protein interactions, and the advancement of novel therapeutics targeting complex medical conditions. For instance, as highlighted in Amgen Inc.'s 2022 annual report, Prolia (Denosumab), a recombinant human monoclonal antibody, experienced a notable 12% growth in annual sales, reaching $3,628 million in 2022 compared to $3,248 million in 2021. Thus, the escalating demand for recombinant proteins acts as a driving force behind the growth of the difficult-to-express protein market.
The burgeoning need for biopharmaceuticals is forecasted to fuel the expansion of the difficult-to-express protein market moving forward. Biopharmaceuticals, derived from biological sources rather than chemical synthesis, are at the forefront of this demand surge. Companies investing in advanced technologies and innovative strategies to overcome expression challenges are generating high-quality, functional proteins. For instance, data from the International Trade Administration in July 2022 indicated that the Pharmaceutical Research and Manufacturers Association (PhRMA) reported approximately $97 billion in research and development spending by biopharmaceutical firms in the U.S. Consequently, the escalating demand for biopharmaceuticals is a significant driver behind the growth of the difficult-to-express protein market.
The difficult-to-express protein market is witnessing a significant trend focused on the development of pioneering technologies. Key companies within this sector are directing their efforts towards innovating technologies to maintain their market foothold. For instance, in January 2023, Evozyne, a biotechnology firm based in the United States, introduced a groundbreaking AI model named Protein Transformer Variational AutoEncoder. This technology serves as a framework adept at effectively training and deploying large language models tailored for biology. The resulting model represents an innovative application of deep learning, presenting new prospects for the data-driven creation of engineered proteins designed with specific functionalities.
A prevalent trend gaining momentum in the difficult-to-express protein market is the substantial increase in investment directed toward enhancing production capacities. For example, in July 2023, Biovian Oy, a Finland-based Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, disclosed a significant investment exceeding €50 million ($53.249 million) to expand its manufacturing facility in Finland. This strategic investment aims to meet the escalating demand for top-tier biopharmaceutical manufacturing services, further solidifying Biovian's position as a reliable partner in the biopharmaceutical industry. The expansion, in conjunction with Biovian's existing facility, will amplify the total area to 111,500 square meters, positioning the company to cater effectively to market demands.
In March 2022, Cobepa Inc., a privately held investment company based in the United States, successfully acquired Reaction Biology Corporation for an undisclosed amount. This strategic acquisition by Cobepa Inc. is intended to provide additional capital and resources to further strengthen Reaction Biology Corporation's capabilities in addressing the dynamic requirements of the biopharmaceutical industry. Reaction Biology Corporation is a biopharmaceutical company based in the United States, specializing in the production of difficult-to-express proteins.
Major companies operating in the difficult-to-express proteins market report are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Samsung Biologics Co. Ltd., Bio-Techne Corp., GenScript Biotech Corporation, Ajinomoto Bio-Pharma Services, Novasep Holding SAS, Rentschler Biopharma SE, BioLegend Inc., Codexis Inc., Enzo Biochem Inc., Sino Biological Inc., Horizon Discovery Ltd., Creative Biolabs Inc., OriGene Technologies Inc., Celonic AG, Cube Biotech GmbH, Lucigen Corporation, Batavia Biosciences Inc., Cytovance Biologics Inc., Alloy Therapeutics Inc., Aragen Bioscience Inc., Selexis SA, LifeSensors Inc., Bionova Scientific Inc.
North America was the largest region in the difficult-to-express proteins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the difficult-to-express proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary categories of difficult-to-express proteins encompass proteases, kinases, membrane proteins, and others. Proteases, for instance, are enzymes that catalyze the breakdown of peptide bonds in proteins. They serve as essential tools in peptide research, showcasing proficiency in breaking down proteins into smaller peptide fragments. This capability facilitates simultaneous mass spectrometry analysis and contributes to the understanding and treatment of various diseases such as inflammation, sepsis, digestive disorders, cystic fibrosis, and retinal disorders. The expression of difficult proteins involves diverse techniques, including disulfide-bonded protein expression, membrane protein expression, toxic protein expression, and addressing target protein insolubility. Various technologies, such as cell-free protein synthesis, prokaryotic expression systems, small ubiquitin-such as modifier (SUMO) fusion systems, and gene fusion systems, are employed to address these challenges. The applications span across critical areas such as drug discovery, protein purification, protein therapeutics, and disease diagnostics and monitoring.
The difficult-to-express proteins market research report is one of a series of new reports that provides difficult-to-express proteins market statistics, including difficult-to-express proteins industry global market size, regional shares, competitors with a difficult-to-express proteins market share, detailed difficult-to-express proteins market segments, market trends and opportunities, and any further data you may need to thrive in the difficult-to-express proteins industry. This difficult-to-express proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The difficult-to-express proteins market consists of revenues earned by entities by providing code optimization, fusion tags, post-translational modification, inducible expression systems, and co-expression chaperones. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficult-to-express protein market also includes the sales of toxoids, antibody fragments, multi-domain proteins, and post-translational modified proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $7.09 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%.The anticipated growth in the forecast period is expected to result from the development of novel expression systems, advancements in next-generation gene editing tools, improvements in cell-free systems, enhanced protein engineering, and the integration of artificial intelligence and machine learning. Key trends expected in the forecast period include the adoption of innovative protein folding technologies, increased utilization of synthetic biology, targeted protein modification, advancements in biophysical characterization, and the expanded use of CRISPR/Cas technology.
The anticipated surge in demand for recombinant proteins is poised to drive the expansion of the difficult-to-express protein market in the foreseeable future. Recombinant proteins, synthesized using modified DNA, play a crucial role in generating the genetic codes necessary for desired proteins. These difficult-to-express proteins, integral in recombinant protein synthesis, enable the exploration of specific activities, protein-protein interactions, and the advancement of novel therapeutics targeting complex medical conditions. For instance, as highlighted in Amgen Inc.'s 2022 annual report, Prolia (Denosumab), a recombinant human monoclonal antibody, experienced a notable 12% growth in annual sales, reaching $3,628 million in 2022 compared to $3,248 million in 2021. Thus, the escalating demand for recombinant proteins acts as a driving force behind the growth of the difficult-to-express protein market.
The burgeoning need for biopharmaceuticals is forecasted to fuel the expansion of the difficult-to-express protein market moving forward. Biopharmaceuticals, derived from biological sources rather than chemical synthesis, are at the forefront of this demand surge. Companies investing in advanced technologies and innovative strategies to overcome expression challenges are generating high-quality, functional proteins. For instance, data from the International Trade Administration in July 2022 indicated that the Pharmaceutical Research and Manufacturers Association (PhRMA) reported approximately $97 billion in research and development spending by biopharmaceutical firms in the U.S. Consequently, the escalating demand for biopharmaceuticals is a significant driver behind the growth of the difficult-to-express protein market.
The difficult-to-express protein market is witnessing a significant trend focused on the development of pioneering technologies. Key companies within this sector are directing their efforts towards innovating technologies to maintain their market foothold. For instance, in January 2023, Evozyne, a biotechnology firm based in the United States, introduced a groundbreaking AI model named Protein Transformer Variational AutoEncoder. This technology serves as a framework adept at effectively training and deploying large language models tailored for biology. The resulting model represents an innovative application of deep learning, presenting new prospects for the data-driven creation of engineered proteins designed with specific functionalities.
A prevalent trend gaining momentum in the difficult-to-express protein market is the substantial increase in investment directed toward enhancing production capacities. For example, in July 2023, Biovian Oy, a Finland-based Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, disclosed a significant investment exceeding €50 million ($53.249 million) to expand its manufacturing facility in Finland. This strategic investment aims to meet the escalating demand for top-tier biopharmaceutical manufacturing services, further solidifying Biovian's position as a reliable partner in the biopharmaceutical industry. The expansion, in conjunction with Biovian's existing facility, will amplify the total area to 111,500 square meters, positioning the company to cater effectively to market demands.
In March 2022, Cobepa Inc., a privately held investment company based in the United States, successfully acquired Reaction Biology Corporation for an undisclosed amount. This strategic acquisition by Cobepa Inc. is intended to provide additional capital and resources to further strengthen Reaction Biology Corporation's capabilities in addressing the dynamic requirements of the biopharmaceutical industry. Reaction Biology Corporation is a biopharmaceutical company based in the United States, specializing in the production of difficult-to-express proteins.
Major companies operating in the difficult-to-express proteins market report are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Samsung Biologics Co. Ltd., Bio-Techne Corp., GenScript Biotech Corporation, Ajinomoto Bio-Pharma Services, Novasep Holding SAS, Rentschler Biopharma SE, BioLegend Inc., Codexis Inc., Enzo Biochem Inc., Sino Biological Inc., Horizon Discovery Ltd., Creative Biolabs Inc., OriGene Technologies Inc., Celonic AG, Cube Biotech GmbH, Lucigen Corporation, Batavia Biosciences Inc., Cytovance Biologics Inc., Alloy Therapeutics Inc., Aragen Bioscience Inc., Selexis SA, LifeSensors Inc., Bionova Scientific Inc.
North America was the largest region in the difficult-to-express proteins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the difficult-to-express proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary categories of difficult-to-express proteins encompass proteases, kinases, membrane proteins, and others. Proteases, for instance, are enzymes that catalyze the breakdown of peptide bonds in proteins. They serve as essential tools in peptide research, showcasing proficiency in breaking down proteins into smaller peptide fragments. This capability facilitates simultaneous mass spectrometry analysis and contributes to the understanding and treatment of various diseases such as inflammation, sepsis, digestive disorders, cystic fibrosis, and retinal disorders. The expression of difficult proteins involves diverse techniques, including disulfide-bonded protein expression, membrane protein expression, toxic protein expression, and addressing target protein insolubility. Various technologies, such as cell-free protein synthesis, prokaryotic expression systems, small ubiquitin-such as modifier (SUMO) fusion systems, and gene fusion systems, are employed to address these challenges. The applications span across critical areas such as drug discovery, protein purification, protein therapeutics, and disease diagnostics and monitoring.
The difficult-to-express proteins market research report is one of a series of new reports that provides difficult-to-express proteins market statistics, including difficult-to-express proteins industry global market size, regional shares, competitors with a difficult-to-express proteins market share, detailed difficult-to-express proteins market segments, market trends and opportunities, and any further data you may need to thrive in the difficult-to-express proteins industry. This difficult-to-express proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The difficult-to-express proteins market consists of revenues earned by entities by providing code optimization, fusion tags, post-translational modification, inducible expression systems, and co-expression chaperones. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficult-to-express protein market also includes the sales of toxoids, antibody fragments, multi-domain proteins, and post-translational modified proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Difficult-to-Express Proteins Market Characteristics3. Difficult-to-Express Proteins Market Trends and Strategies32. Global Difficult-to-Express Proteins Market Competitive Benchmarking33. Global Difficult-to-Express Proteins Market Competitive Dashboard34. Key Mergers and Acquisitions in the Difficult-to-Express Proteins Market
4. Difficult-to-Express Proteins Market - Macro Economic Scenario
5. Global Difficult-to-Express Proteins Market Size and Growth
6. Difficult-to-Express Proteins Market Segmentation
7. Difficult-to-Express Proteins Market Regional and Country Analysis
8. Asia-Pacific Difficult-to-Express Proteins Market
9. China Difficult-to-Express Proteins Market
10. India Difficult-to-Express Proteins Market
11. Japan Difficult-to-Express Proteins Market
12. Australia Difficult-to-Express Proteins Market
13. Indonesia Difficult-to-Express Proteins Market
14. South Korea Difficult-to-Express Proteins Market
15. Western Europe Difficult-to-Express Proteins Market
16. UK Difficult-to-Express Proteins Market
17. Germany Difficult-to-Express Proteins Market
18. France Difficult-to-Express Proteins Market
19. Italy Difficult-to-Express Proteins Market
20. Spain Difficult-to-Express Proteins Market
21. Eastern Europe Difficult-to-Express Proteins Market
22. Russia Difficult-to-Express Proteins Market
23. North America Difficult-to-Express Proteins Market
24. USA Difficult-to-Express Proteins Market
25. Canada Difficult-to-Express Proteins Market
26. South America Difficult-to-Express Proteins Market
27. Brazil Difficult-to-Express Proteins Market
28. Middle East Difficult-to-Express Proteins Market
29. Africa Difficult-to-Express Proteins Market
30. Difficult-to-Express Proteins Market Competitive Landscape and Company Profiles
31. Difficult-to-Express Proteins Market Other Major and Innovative Companies
35. Difficult-to-Express Proteins Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Difficult-to-Express Proteins Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on difficult-to-express proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for difficult-to-express proteins? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Protein: Proteases; Kinases; Membrane Proteins; Other Proteins
2) By Expression Of Difficult Proteins: Disulfide-bonded Protein Expression; Membrane Protein Expression; Toxic Protein Expression; Target Protein Insolubility
3) By Technology: Cell-free Protein Synthesis; Prokaryotic Expression Systems; Small Ubiquitin-like Modifier (SUMO) Fusion System; Gene Fusion Systems; Other Technologies
4) By Application: Drug Discovery; Protein Purification; Protein Therapeutics; Disease Diagnostics and Monitoring; Other Applications
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Lonza Group Ltd; Catalent Inc.; Sartorius AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Lonza Group Ltd
- Catalent Inc.
- Sartorius AG
- Charles River Laboratories International Inc.
- Bio-Rad Laboratories Inc.
- Samsung Biologics Co. Ltd.
- Bio-Techne Corp.
- GenScript Biotech Corporation
- Ajinomoto Bio-Pharma Services
- Novasep Holding SAS
- Rentschler Biopharma SE
- BioLegend Inc.
- Codexis Inc.
- Enzo Biochem Inc.
- Sino Biological Inc.
- Horizon Discovery Ltd.
- Creative Biolabs Inc.
- OriGene Technologies Inc.
- Celonic AG
- Cube Biotech GmbH
- Lucigen Corporation
- Batavia Biosciences Inc.
- Cytovance Biologics Inc.
- Alloy Therapeutics Inc.
- Aragen Bioscience Inc.
- Selexis SA
- LifeSensors Inc.
- Bionova Scientific Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 4.63 Billion |
Forecasted Market Value ( USD | $ 7.09 Billion |
Compound Annual Growth Rate | 11.3% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |